A.I. BURNASYAN FMBC CLINICAL BULLETIN

ISSN 2782-6430 (print)

State Research Center −Burnasyan Federal Medical Biophysical
Center of Federal Medical Biological Agency

The journal is published in Russian.
Format – A4.
The periodicity of the journal is 4 times a year.

Issue №1, 2026

more

A.I. Burnasyan  FMBC clinical bulletin. 2025 № 4

 

A.E. Krasnov1, Yu.D. Udalov1, E.N. Mingazova2,3,4

Comorbidity and Multimorbidity from the Point of Risk Assessment and Assistance
to Patients with Chronic Pathology at Infectious Risks

1International Office, State Research Center – Burnasyan Federal Medical Biophysical Center of Federal Medical Biological Agency, Moscow, Russiа

2N.A. Semashko National Research Institute of Public Health

3Kazan State Medical University

4Russian Medical Academy of Continuous Professional Education

Contact person: Mingazova Elmira Nurislamovna: elmira_mingazova@mail.ru

 

Abstract
Background: The article examines the problem of comorbidity and multimorbidity from the perspective of health risks for patients, treatment outcomes and burden on the healthcare system. Particular attention is paid to the differences between these concepts, their prevalence among different population groups, as well as the role of comorbidity in aggravating the course of infectious diseases, including COVID-19. Key comorbidity clusters are analyzed in detail: cardiovascular, respiratory and oncological diseases, as well as their mutual influence. Modern methods of parametric comorbidity assessment, such as the Charlson index and the Elixhauser index, and their application in clinical practice are considered. Comorbidity management strategies are highlighted, including a multidisciplinary approach, personalized medicine and digital technologies. Particular emphasis is placed on global and regional features of the organization of medical care for patients with multiple chronic diseases, as well as on lessons learned during the COVID-19 pandemic.

Keywords: comorbidity, multimorbidity, chronic diseases, infectious diseases, COVID-19, personalized medicine, multidisciplinary approach, healthcare system

For citation: Krasnov AE, Udalov YuD, Mingazova EN. Comorbidity and Multimorbidity from the Point of Risk Assessment and Assistance to Patients with Chronic Pathology at Infectious Risks. A.I. Burnasyan Federal Medical Biophysical Center Clinical Bulletin. 2025.4:90-95. (In Russian) DOI: 10.33266/2782-6430-2025-4-90-95

 

REFERENCES

  1. Kizeyev M.V., Lazarev A.V., Valeyev V.V., et al. Age-Related Features of Population Morbidity in the Context of the COVID-19 Pandemic. Problemy Sotsial’noy Gigiyeny, Zdravookhraneniya i Istorii Meditsiny = Problems of Social Hygiene, Public Health and History of Medicine. 2022;30;S1:1023–1026 (In Russ.). doi: 10.32687/0869-866X-2022-30-s1-1023-1026.
  2. Khabriyev R.U., Mingazova E.N., Ziatdinov V.B., et al. Forecast of Birth Rate and Morbidity of the Population of the Constituent Entities of the Russian Federation from the Standpoint of Assessing the Reproductive Potential. Zdravookhraneniye Rossiyskoy Federatsii = Health Care of the Russian Federation. 2021;65;6:507–513 (In Russ.). doi: 10.47470/0044-197X-2021-65-6-507-513.
  3. Khabriyev R.U., Mingazova E.N., Shigabutdinova T.N. Main Trends of Medical and Demographic Indicators in the Republic of Tatarstan (1991–2018). Obshchestvennoye Zdorov’ye i Zdravookhraneniye = Public Health and Health Care. 2019;3;63:5–10 (In Russ.).
  4. Mingazova E.N., Bakirova E.A., Shigabutdinova T.N. Dynamics of Changes and Prognostic Models of Morbidity Levels of the Urban and Rural Population of a Constituent Entity of the Russian Federation. Problemy Sotsial’noy Gigiyeny, Zdravookhraneniya i Istorii Meditsiny = Problems of Social Hygiene, Public Health and History of Medicine. 2021;29;6:1505–1509 (In Russ.). doi: 10.32687/0869-866X-2021-29-6-1505-1509.
  5. Mingazova E.N., Zhelezova P.V., Mingazov R.N. Population Size of the Region from the Point of View of its Reproductive and Demographic Potential. Menedzher Zdravookhraneniya = Health Care Manager. 2024;1:11–22 (In Russ.). doi: 10.21045/1811-0185-2024-1-11-22.
  6. Lebedeva U.M., Mingazova E.N. Dynamic Monitoring of Changes in Medical and Demographic Indicators in the Republic of Sakha (Yakutia) for 1998–2018. Dal’nevostochnyy Meditsinskiy Zhurnal = Far Eastern Medical Journal. 2020;4:33–36 (In Russ.). doi: 10.35177/1994-5191-2020-4-33-36.
  7. Muslimov M.I., Gureyev S.A., Mingazova E.N. On the Issue of Public and Population Health. Menedzher Zdravookhraneniya = Health Care Manager. 2024;7:97–105 (In Russ.). doi: 10.21045/1811-0185-2024-7-97-105.
  8. Aramisova L.S., Zhurtova I.B., Khachmakhova E.Z. Analysis of the Prognostic Quality of Mortality Predictors in Patients with COVID-19 and Comorbid Background: a Retrospective Study. Farmateka = Pharmateka. 2025;32;2:124–128 (In Russ). doi: 10.18565/pharmateca.2025.2.124-128.
  9. Oganov R.G., Simanenkov V.I., Bakulin I.G., et al. Comorbid Pathology in Clinical Practice. Diagnostic and Treatment Algorithms. Kardiovaskulyarnaya Terapiya i Profilaktika = Cardiovascular Therapy and Prevention. 2019;18;1:5–66 (In Russ.). doi: 10.15829/1728-8800-2019-1-5-66.
  10. Khabriyev R.U., Krasnov A.Ye., Mingazova E.N. Dynamic and Prognostic Indicators of Mortality of the Working-Age Male and Female Population, Taking into Account their Characteristics before and during COVID-19. Kazanskiy Meditsinskiy Zhurnal = Kazan Medical Journal. 2025;106;3:446-453 (In Russ). doi: 10.17816/KMJ640159.
  11. Krasnov A.Ye., Bakirova E.A., Mingazova E.N. Comprehensive Analysis of Mortality by Causes: Regional Characteristics. Problemy Sotsial’noy Gigiyeny, Zdravookhraneniya i Istorii Meditsiny = Problems of Social Hygiene, Public Health and History of Medicine. 2024;32;S1:628–632 (In Russ.). doi: 10.32687/0869-866X-2024-32-s1-628-632.
  12. Krasnov A.Ye., Mingazova E.N. Mortality of the Population in the 21st Century: Regional Characteristics. Byulleten‘ Natsional’nogo Nauchno-Issledovatel’skogo Instituta Obshchestvennogo Zdorov’ya Imeni N.A. Semashko = Bulletin of the National Research Institute of Public Health Named after N.A.Semashko. 2024;1:96–101 (In Russ). doi: 10.25742/NRIPH.2024.01.015.
  13. Starfield B. Challenges to Primary Care from Co- and Multi-Morbidity. Primary Health Care Research & Development. 2011;12;1:1–2. doi: 10.1017/S1463423610000484.
  14. Drapkina O.M., Shutov A.M., Yefremova Ye.V. Comorbidity, Multimorbidity, Dual Diagnosis – Synonyms or Different Concepts? Kardiovaskulyarnaya Terapiya i Profilaktika = Cardiovascular Therapy and Prevention. 2019;18;2:65–69 (In Russ). doi: 10.15829/1728-8800-2019-2-65-69.
  15. Marengoni A., Angleman S., Melis R., et al. Aging with Multimorbidity: a Systematic Review of the Literature. Ageing Research Reviews. 2011;10;4:430–439. doi: 10.1016/j.arr.2011.03.003.
  16. Tarlovskaya Ye.I. Comorbidity and Polymorbidity – Modern Interpretation and Pressing Tasks Facing the Therapeutic Community. Kardiologiya = Cardiology. 2018;58;S9:29–38 (In Russ.).
  17. Barnett K., Mercer S.W., Norbury M., et al. Epidemiology of Multimorbidity and Implications for Health Care, Research, and Medical Education: a Cross-Sectional Study. The Lancet. 2012;380;9836:37–43. doi: 10.1016/S0140-6736(12)60240-2.
  18. Krasnov A.Ye., Mingazova E.N. Indicators of Primary Health Care to the Population, Taking into Account the Medical and Demographic Characteristics of the Region. Menedzher Zdravookhraneniya = Health Care Manager. 2023;11:10–16 (In Russ.). doi: 10.21045/1811-0185-2023-11-10-16.
  19. Rizzuto D., Melis R.J.F., Angleman S., et al. Effect of Chronic Diseases and Multimorbidity on Survival and Functioning in Elderly Adults. Journal of the American Geriatrics Society. 2017;65;5:1056–1060. doi: 10.1111/jgs.14868.
  20. Korkhmazov V.T., Perkhov V.I. Lessons of the COVID-19 Pandemic for Project Management in Healthcare. Meditsina i Organizatsiya Zdravookhraneniya = Medicine and Health Care Organization. 2023;8;3:13–25 (In Russ.). doi: 10.56871/MHCO.2023.62.30.002.
  21. Perkhov V.I., Korkhmazov V.T. Dynamics of Quantitative Indicators of the Federal Project «Combating Cardiovascular Diseases» during the COVID-19 Pandemic. Nauka i Innovatsii v Meditsine = Science & Innovations in Medicine. 2023;8;4:287–293 (In Russ.). doi: 10.35693/2500-1388-2023-8-4-287-293.
  22. Smirnov A.A., Luk’yanov M.M., Martsevich S.Yu., et al. Clinical and Anamnestic Characteristics, Cardiovascular Pharmacotherapy and Long-Term Outcomes in Multimorbid Patients who Had COVID-19. Ratsional’naya Farmakoterapiya v Kardiologii = Rational Pharmacotherapy in Cardiology. 2022;18;5:502–509 (In Russ.). doi: 10.20996/1819-6446-2022-09-06.
  23. Dunlay S.M., Chamberlain A.M. Multimorbidity in Older Patients with Cardiovascular Disease. Current Cardiovascular Risk Reports. 2016;10:3. doi: 10.1007/s12170-016-0491-8.
  24. Fox C.S., Coady S., Sorlie P.D., et al. Trends in Cardiovascular Complications of Diabetes. JAMA. 2004;292;20:2495–2499. doi: 10.1001/jama.292.20.2495.
  25. Gao M., Piernas C., Astbury N.M., et al. Associations between Body-Mass Index and COVID-19 Severity in 6.9 million People in England: a Prospective, Community-Based, Cohort Study. The Lancet Diabetes & Endocrinology. 2021;9;6:350–359. doi: 10.1016/S2213-8587(21)00089-9.
  26. Abumweis S., Alrefai W., Alzoughool F. Association of Obesity with COVID-19 Disease Severity and Mortality: A Meta-Analysis of Studies. Obesity Medicine. 2022;33:100431. doi: 10.1016/j.obmed.2022.100431.
  27. Sarfati D., Koczwara B., Jackson C. The Impact of Comorbidity on Cancer and its Treatment. CA. A Cancer Journal for Clinicians. 2016;66;4:337–350. doi: 10.3322/caac.21342.
  28. Fowler H., Belot A., Ellis L., et al. Comorbidity Prevalence among Cancer Patients: a Population-Based Cohort Study of Four Cancers. BMC Cancer. 2020;20:2. doi: 10.1186/s12885-019-6472-9.
  29. Naumova O.A., Efros L.A. Common Methods for Assessing Comorbidity (Literature Review). Mezhdunarodnyy Nauchno-Issledovatel’skiy Zhurnal = International Research Journal. 2022;12;126:61 (In Russ.). doi: 10.23670/IRJ.2022.126.61.
  30. Tuty Kuswardhani R.A., Henrina J., Pranata R., et al. Charlson Comorbidity Index and a Composite of Poor Outcomes in COVID-19 Patients: A Systematic Review and Meta-Analysis. Diabetes & Metabolic Syndrome. 2020;14;6:2103–2109. doi: 10.1016/j.dsx.2020.10.022.
  31. Comoglu S., Kant A. Does the Charlson Comorbidity Index Help Predict the Risk of Death in COVID-19 Patients? Northern Clinics of Istanbul. 2022;9;2:117–121. doi: 10.14744/nci.2022.33349.
  32. Zhou W., Qin X., Hu X., et al. Prognosis Models for Severe and Critical COVID-19 Based on the Charlson and Elixhauser Comorbidity Indices. International Journal of Medical Sciences. 2020;17;15:2257–2263. doi: 10.7150/ijms.50007.
  33. Endalamaw A., Zewdie A., Wolka E., Assefa Y. Care Models for Individuals with Chronic Multimorbidity: Lessons for Low- and Middle-Income Countries. BMC Health Services Research. 2024;24:895. doi: 10.1186/s12913-024-11351-y.
  34. Strianese O., Rizzo F., Ciccarelli M., et al. Precision and Personalized Medicine: how Genomic Approach Improves the Management of Cardiovascular and Neurodegenerative Disease. Genes. 2020;11;7:747. doi: 10.3390/genes11070747.
  35. Fadeeva S.A., Sitdikova I.D., Mingazova E.N., et al. Risk Assessment as a Criterion of Environmental Stress. Indo American Journal of Pharmaceutical Sciences. 2018;5;9:9323–9327. doi: 10.5281/zenodo.1439332.
  36. Sitdikova I.D., Mingazova E.N., Meshkov A.V., Gureyev S.A. Risk Assessment as a Criterion in the System of Public Health Indicators.  Byulleten‘ Natsional’nogo Nauchno-Issledovatel’skogo Instituta Obshchestvennogo Zdorov’ya imeni N.A. Semashko = Bulletin of the National Research Institute of Public Health Named after N.A. Semashko. 2020;1:24–29 (In Russ.). doi: 10.25742/NRIPH.2020.01.004.
  37. Hare A.J., Chokshi N., Adusumalli S. Novel Digital Technologies for Blood Pressure Monitoring and Hypertension Management. Current Cardiovascular Risk Reports. 2021;15;8:11. doi: 10.1007/s12170-021-00672-w.
  38. Aubrey-Bassler K., Fernandes C., Penney C., et al. The Effectiveness of a Proven Chronic Disease Prevention and Screening Intervention in Diverse and Remote Primary Care Settings: an Implementation Study on the BETTER 2 Program. BJGP Open. 2019;3;3. doi: 10.3399/bjgpopen19X101656.
  39. Bakirova E.A., Mingazova E.N. Improving Medical Care for the Rural Population Through Business Process Management. Menedzher Zdravookhraneniya = Health Care Manager. 2020;8:20–26 (In Russ.). doi: 10.37690/1811-0185-2020-8-20-26.
  40. Vest J.R., Gamm L.D. Health Information Exchange: Persistent Challenges and New Strategies. Journal of the American Medical Informatics Association. 2010;17;3:288–294. doi: 10.1136/jamia.2010.003673.
  41. Struckmann V., Leijten F.R.M., van Ginneken E., et al. Relevant Models and Elements of Integrated Care for Multi-Morbidity: Results of a Scoping Review. Health Policy. 2018;122;1:23-35. doi: 10.1016/j.healthpol.2017.08.008.
  42. Lewinski A.A., Walsh C., Rushton S., et al. Telehealth for the Longitudinal Management of Chronic Conditions: Systematic Review. Journal of Medical Internet Research. 2022;24;8:e37100. doi: 10.2196/37100.
  43. Lewinski A.A., Walsh C., Rushton S., et al. Telehealth for the Longitudinal Management of Chronic Conditions: Systematic Review. Journal of Medical Internet Research. 2022;24;8:e37100. doi: 10.2196/37100.
  44. Drapkina O.M., Kontsevaya A.V., Kalinina A.M., et al. Comorbidity of Patients with Chronic Non-Infectious Diseases in the Practice of a General Practitioner. Eurasian Guide. Kardiovaskulyarnaya Terapiya i Profilaktika = Cardiovascular Therapy and Prevention. 2024;23;3:113–418 (In Russ).

Conflict of interest. The authors declare no conflict of interest.
Financing. The study had no sponsorship.
Contribution. Article was prepared with equal participation of the authors.
Article received: 08.07.2025. Accepted for publication: 13.08.2025

© 2026 Scientific journal - "Clinical Bulletin of the FMBС im. A.I. Burnasyan"
Scroll to Top